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Abstract
MicroRNAs (MiRNAs) are short, non-coding RNA that regulate a variety of cellular functions by suppressing target protein
expression. We hypothesized that a set of microRNA regulate tumor responses to hypoxia by inhibiting components of the
hypoxia signaling pathway. We found that miR-22 expression in human colon cancer is lower than in normal colon tissue.
We also found that miR-22 controls hypoxia inducible factor 1a (HIF-1a) expression in the HCT116 colon cancer cell line.
Over-expression of miR-22 inhibits HIF-1a expression, repressing vascular endothelial growth factor (VEGF) production
during hypoxia. Conversely, knockdown of endogenous miR-22 enhances hypoxia induced expression of HIF-1a and VEGF.
The conditioned media from cells over-expressing miR-22 contain less VEGF protein than control cells, and also induce less
endothelial cell growth and invasion, suggesting miR-22 in adjacent cells influences endothelial cell function. Taken
together, our data suggest that miR-22 might have an anti-angiogenic effect in colon cancer.
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Introduction
MicroRNAs (MiRNAs) are short non-coding RNAs (18–22 nt),
which inhibit gene expression. Mature miRNAs are produced by
the RNase III enzymes Drosha and Dicer, then incorporate into
the RNA-induced silencing complex (RISC), and finally bind to
the 39-untranslated region (39-UTR) of their target gene mRNAs,
inhibiting their expression[1,2]. It is believed that consecutive base
pairing of at least 7 nucleotides between the miRNA sequence
(seed sequence) and the miRNA recognition element (MRE) is
necessary to repress protein translation[3,4,5,6,7]. In addition,
some studies suggest that imperfect binding such as wobbles or
bulges in the seed sequence inhibits protein translation [8,9].
MiRNAs have a variety of physiological and pathological
functions, including control of tumorigenesis[10,11,12]. The
transcription factor most commonly mutated in cancer, p53,
regulates a set of miRNAs. Activation of p53 increases miR-34a
production, and over-expression of miR-34a induces cell cycle
arrest, senescence and apoptosis. Another transcription factor
linked to cancer, c-myc, regulates a separate set of miRNA. C-myc
decreases the expression of several miRNAs including miR-22 in
cancer cell lines[13]. Recent studies showed that miR-22 targets
several proteins such as estrogen receptor a (ERa), c-Myc binding
protein (MYCBP), Myc associated factor X (MAX), and PTEN,
suggesting that miR-22 may be implicated in tumorigenesis.
However the function of miR-22 in cancer cells remains unknown.
Hypoxia inducible factor 1 (HIF-1) is a heterodimeric trans-
cription factor that regulates transcription of genes such as
vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) [14,15,16]. HIF-1 is a heterodimer con-
sisting of two subunits, HIF-1a and HIF-1b (ARNT). Hypoxia or
hypoxia mimetics stabilize HIF-1a by inhibiting its prolyl
hydroxylation. HIF-1 is involved in angiogenesis, invasion,
metastasis, glucose uptake and metabolism in cancer cells[17].
Hypoxia in tumors can act as a trigger for angiogenesis to deliver
increased oxygen to the cancer. HIF-1a expression is associated
with poor prognosis in colorectal cancer and pancreatic can-
cer[17,18,19].
We now identify HIF-1a as a target for miR-22 in a colon
cancer cell line. We find that miR-22 levels in human colon cancer
are lower than in normal colon tissue. Since colon cancer
specimens with lower miR-22 show higher VEGF expression, we
hypothesize that miR-22 regulates hypoxia signaling in colon
cancer cell lines.
Results
Expression of miR-22 in colon cancer
We first used Northern blotting to measure miR-22 expression
in human tissues, and found that miR-22 is expressed in most
tissues, but relatively abundant in heart, smooth muscle, bladder,
and adipose tissue (Fig. 1A). We next examined the expression of
miR-22 in several cancer cell lines. We could detect miR-22 in
three colon cancer cell lines, HCT116, HCT116 p53 KO and
HT29, and also in an epithelial cancer cell line, HeLa (Fig. 1B). To
examine the level of miR-22 in colon cancer, we measured miR-22
expression by qPCR in 9 human colon cancer specimens and 9
normal colon tissues from patients at The Johns Hopkins Hospital.
Expression of miR-22 is lower in colon cancer specimens (P=0.02)
(Fig. 1C). Since we are interested in studying how microRNA
regulate tumor angiogenesis, we also measured VEGF mRNA
expression in the same samples and found that VEGF mRNA
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colon specimens (P=0.03) (Fig.1C). We also found that RNA
levels of miR-22 and VEGF are negatively correlated (P,0.05)
(Fig. 1D).
HIF-1a is a target of miR-22
Since HIF-1a is part of a major oxygen sensing pathway, we
searched for potential miRNA that might control HIF-1a
translation using computational analysis (Human miRNA Targets
at the Memorial Sloan-Kettering Cancer Center Computational
Biology web site http://cbio.mskcc.org/cgi-bin/mirnaviewer/
mirnaviewer.pl), and found that the miR-22 seed sequence
matches the 39 UTR of HIF-1a (7 nucleotides matches including
one wobble match). We explored how miR-22 regulates HIF-1
and hypoxia signaling using HCT116 colon cancer cells as an in
vitro model of how tumor cells respond to hypoxia. To examine if
miR-22 regulates HIF-1a protein expression, we transfected
HCT116 cells with pre-miR-22 for over expression of miR-22
and with anti-sense-miR-22 for knockdown of miR-22. Transfec-
tion of pre-miR-22 into HCT116 increased miR-22 levels more
than 10 fold (Fig. 2A). Knockdown of miR-22 by transfecting with
anti-sense-miR-22 decreased miR-22 levels down to 40% (Fig. 2A).
Hypoxia increased HIF-1a expression in HCT116, as expected
(Fig. 2B). However, over-expression of miR-22 inhibited hypoxia-
induced HIF-1a expression in HCT116 and HT29 (Fig. 2B–D). In
contrast, knockdown of miR-22 enhanced HIF-1a expression
under hypoxia (Fig. 2C–D). Over-expression of miR-22 did not
alter the level of HIF-1b, the dimerization partner of HIF-1a
(Figure S1). These studies show that endogenous miR-22 inhibits
HIF-1a.
Figure 1. Expression of miR-22 in human cells, normal human colon tissue and human colon cancer. (A) MiR-22 expression in normal
human tissues. A commercial membrane containing RNA from normal human tissues was probed for miR-22 using Northern analysis. (B) MiR-22
expression in cell lines. Cell lysates were probed for miR-22 by Northern blotting. (C) MiR-22 and VEGF expression in normal human colon tissue and
human colon cancer. RNA was extracted from 9 normal human colon specimens (white) and from 9 human colon cancer specimens (black), and
analyzed by qPCR for miR-22 and VEGF expression (n=96 S.D.). Colon cancer specimens contain less miR-22 and more VEGF than normal colon
specimens. (D) The association of miR-22 and VEGF in human colon cancer. Natural log transformation of relative ratio of RNA for miR-22 and VEGF
was used for statistical analysis (n=30).
doi:10.1371/journal.pone.0020291.g001
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translation. Over-expression or knockdown of miR-22 did not
alter the expression of HIF-1a mRNA, which suggests that miR-
22 regulates HIF-1a translation but not transcription (Fig. 3A).
Human HIF-1a 39 UTR has a potential binding site for miR-22
(Fig. 3B). To explore the mechanism by which miR-22 regulates
HIF-1a, we made a luciferase reporter vector, which contains a
fragment of the 39 UTR of HIF-1a (extending after the stop codon
from 0 to 401 bp) that includes a miR-22 binding site. We co-
transfected HCT116 cells with this reporter vector and with pre-
miR-22 or control. Over-expression of miR-22 decreased
luciferase activity (Fig. 3C left). However, miR-22 does not affect
the expression of luciferase with a mutated miR-22 binding
elements (Fig. 3C right), suggesting that miR-22 inhibits HIF-1a
expression via interaction with the 39 UTR of HIF-1a.
MiR-22 controls VEGF expression in HCT116
To investigate the role of miR-22 in VEGF expression, we
transfected HCT116 with pre-miR-22 or anti-sense-miR-22 or
control, and then measured VEGF mRNA expression by qPCR.
Hypoxia and the hypoxia mimetic desferioxamine (DFX)
increased the expression of VEGF mRNA (Fig. 4A, white bars).
Over-expression of miR-22 decreased hypoxia or DFX induced
VEGF expression (Fig. 4A, black bars). Conversely, knockdown of
miR-22 increased DFX induced VEGF expression (Fig. 4B). Next
we measured the concentration of VEGF in the media. DFX
increased the secretion of VEGF from HCT116 cells. Over-
expression of miR-22 suppressed the secretion of VEGF. In
contrast, knockdown of miR-22 enhanced VEGF release (Fig. 4C–
D). Furthermore, we examined the effect of miR-22 upon
expression of angiopoietin 2 (ANGPT2) and stem cell factor
(SCF), because ANGPT2 and SCF are angiogenic growth factors
that are regulated by HIF-1[20]. Hypoxia induced ANGPT2 and
SCF, and over-expression of miR-22 inhibited hypoxia induced
expression of ANGPT2 and SCF (Figure S2).
MiR-22 in HCT116 regulates endothelial cell growth
Since angiogenesis involves endothelial cell proliferation, we
tested the effect of miR-22 upon HUVEC proliferation. We
transfected HCT116 cells with pre-miR-22 or control, exposed the
cells to normoxia or hypoxia, and harvested the media. We added
this conditioned media to human primary endothelial cell
(HUVEC), cultured for another 3 days, and then measured the
proliferation of HVUEC by BrdU incorporation assay. There was
no significant difference between media from normoxia cells
transfected pre-miR-22 and media from normoxia cells transfected
control (Fig. 5A). As expected, media from hypoxic cells
transfected with control increased HUVEC proliferation. Howev-
er, media from hypoxic cells transfected pre-miR-22 blocked this
increase in proliferation (Fig. 5A).
Since angiogenesis also involves endothelial migration, we
tested the effect of miR-22 upon HUVEC migration using the
scratch wound healing assay. We added to HUVEC cells the
conditioned media from HCT116 cells which had been
Figure 2. HIF-1a is a target of miR-22. (A) Alteration of miR-22 expression by transfection. HCT116 cells were transfected with pre-miR-22 or anti-
sense-miR-22 or control oligonucleotides, and levels of miR-22 were measured by qPCR. (B) Over-expression of miR-22 inhibits HIF-1a expression.
HCT116 cells were transfected with control oligonucleotides or pre-miR-22, and then exposed to normoxia or hypoxia for 16 h. Cell lysates were
immunoblotted for HIF-1a. Hypoxia induces HIF-1a, but miR-22 suppresses HIF-1a. (C) Two colon cancer cell lines, HCT116 (two upper panels) and
HT29 (two bottom panels), were transfected with pre-miR-22 or anti-sense-miR-22, exposed to hypoxia, and cell lysates were immunoblotted for HIF-
1a. (D) Quantification by densitometry of immunoblotting for HIF-1a in HCT116 cells transfected as above (n=36 S.D.).
doi:10.1371/journal.pone.0020291.g002
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exposed to normoxia or hypoxia. After 16 h we measured
endothelial migration from the edge of the scratch wound. Media
from HCT116 cells exposed to hypoxia increased endothelial
migration (Fig. 5B–C). Over-expression of miR-22 in HCT116
slowed HUVEC migration (Fig. 5B–C). These data suggested
that miR-22 in HCT116 affects endothelial biology, increasing
proliferation and migration.
Discussion
The major finding of this study is that miR-22 inhibits hypoxia
signaling. MiR-22 is expressed in many cancer cells including the
colon cancer cell line HCT116. Furthermore, miR-22 suppresses
HIF-1a translation. Finally, miR-22 inhibits VEGF expression by
suppressing HIF-1a expression. Since others have shown that c-
myc limits miR-22 expression, tumors over-expressing c-myc
might be expected to have lower levels of miR-22, higher levels of
HIF-1a and VEGF. Therefore these data suggest that miR-22
may regulate tumor angiogenesis.
Targets of miR-22
Individual miRNA can modulate expression of many genes.
Several reports identify potential targets of miR-22 by using
software algorithms, such as TargetScan, miRanda and PicTar, in
combination with cellular studies. MiR-22 targets estrogen
receptor a (ERa) and represses estrogen signaling in several breast
cancer cell lines [21,22]. MiR-22 also repressed c-Myc-binding
protein MYCBP[23], c-Myc binding partner MAX[24] and tumor
suppressor gene PTEN[25,26,27]. PPAR-alpha and BMP7 are
also targets of miR-22[28]. We found that HIF-1a is a new target
of miR-22. The 39 UTR of HIF-1a includes a complementary
sequence for miR-22 consisting of 7 nucleotides; this seed
sequence contains one wobble binding nucleotide (G–A). Our
biochemical data suggests that miR-22 directly regulates HIF-1a
expression buy suppressing the translation of HIF-1a.
Role of miR-22 in tumor angiogenesis
MiR-22 has unique roles in specific cell types. MiR-22 regulates
the differentiation of a monocyte cell line[24]. MiR-22 regulates
Figure 3. MiR-22 regulates HIF-1a by inhibiting its translation. (A) MiR-22 does not affect HIF-1a mRNA. HCT116 cells were transfected with
Pre-miR-22 or anti-sense-miR-22 or control. Total RNA was harvested and analyzed for HIF-1a mRNA by qPCR (n=36 S.D.). (B) Human HIF-1a 39UTR
contains a binding site for miR-22. (C) MiR-22 represses transactivation of HIF-1a 39UTR. HCT116 cells were transfected with a luciferase reporter
vector (MiRreport) containing the 39 UTR of HIF-1a (left panel) or a mutated 39UTR of HIF-1a (right panel) and with pre-miR-22 or pre-miR-control.
Cells were harvested and luciferase activity was measured (n=36 S.D.).
doi:10.1371/journal.pone.0020291.g003
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cytes[28]. In cancer, the function of miR-22 is controversial. The
mouse miR-22 gene is mapped to a cancer-associated genomic
region, and the human miR-22 gene lies within a loss of
heterozygosity region (LOH) in several cancer cells[23,29],
suggesting that miR-22 is involved in suppressing tumor growth.
Ectopic expression of miR-22 inhibited the proliferation and
colony formation of MCF-7 cells[23]. This tumor suppressor
activity of miR-22 involves repression of MYCBP. However others
have shown that that knockdown of miR-22 increases apoptosis
rate in 16HBE-T cells[26]. The apparent contradiction between
these two studies may be due to different cell lines or different
methods for altering miR-22 levels. We found that miR-22 inhibits
VEGF secretion, suggesting miR-22 may act as an anti-
angiogenesis factor in colon cancer cell lines. Our human data
support this idea: human specimens of colon cancer have lower
levels of miR-22 and higher levels of VEGF, compared with
normal human colon tissue. Our data reveal another mechanism
through which miR-22 might act as a tumor suppressor: loss of
miR-22 expression not only permits an increase in MYCBP but
also an increase in HIF-1a.
Hypoxia signaling and miRNA
Local tumor growth is limited by hypoxia: as the tumor
expands, its center becomes hypoxic, inducing genes such as
VEGF which trigger angiogenesis[30,31,32]. The HIF-1 hetero-
dimer plays a critical role in hypoxic signaling in tumors[15,33].
We and others have identified miRNA that control hypoxia
signaling. We previously found that miR-107 inhibits HIF-1b[34].
Others have shown that miR-20b limits HIF-1a expression in lung
adenocarcinoma and breast cancer cell lines[35,36,37]. The miR-
17-92 cluster also modulates tumor growth by inhibiting HIF-1a
expression. Our current study adds miR-22 to the list of miRNAs
that regulate HIF-1 protein.
Materials and Methods
Cell Culture, Hypoxia exposure and Transfection
Human umbilical vein endothelial cells (HUVEC) were
purchased from Lonza (Walkersville, MD). HUVEC (passage 2-
5) were cultured in endothelial basal medium (EBM2) supple-
mented with growth factors (Lonza). HeLa and HEK293 (ATCC,
Manassas, VA) were cultured in DMEM media (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS).
HCT116 (gift from Bert Vogelstein, The Johns Hopkins
University School of Medicine) and HT29 (ATCC) were cultured
in McCoy9s 5A media supplemented with 10% FBS. Desferriox-
amine (DFX) and other reagents were obtained from Sigma (St
Louis, MO). To expose cells to hypoxia, cells were cultured in
Billups-Rotenburg chamber with 94% N2, 1% O2, and 5% CO2
on 37 C for 24 hours.
Human Specimen
Human colon cancer specimens (n=9) and paired non-
cancerous normal colon specimen (n=9) were obtained from
patients at The Johns Hopkins Hospital, Baltimore, MD, with
documented informed consent in each case. The collection and
analysis of human colon cancer specimen were approved by The
Figure 4. MiR-22 regulates VEGF expression and secretion. HCT116 were transfected with pre-miR-22 or anti-sense-miR-22 or control, and
then exposed to normoxia or hypoxia for 16 h. The media was analyzed for VEGF by ELISA and RNA from cell lysates was analyzed for VEGF mRNA by
qPCR (n=36 S.D. *P,0.05) (A) Pre-miR-22 decreases VEGF mRNA. (B) Anti-sense-miR-22 increases VEGF mRNA. (C) Pre-miR-22 decreases VEGF
protein. (D) Anti-sense-miR-22 increases VEGF protein.
doi:10.1371/journal.pone.0020291.g004
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Board. Patients undergoing surgery for colorectal cancers provided
written consent to donate tissue for analysis.
Transfection
Precursor miRNAs and anti-sense oligonucleotides for miRNAs
were from Applied Biosystems (Foster City, CA). For transfection
of precursor miRNA, HCT116 cells were transfected with
siPORT NeoFX (Applied Biosystems) with precursor miRNA 0–
20 nM or with anti-sense miRNA 0–40 nM and harvested
48 hours later.
Northern blotting
Total RNAs were extracted from cells using Trizol (Invitrogen).
Human tissue RNAs were obtained from Applied Biosystems.
Northern blotting for miR-22 was performed as described
previously. Briefly, 10 mg of each RNA were loaded onto 15%
TBU-gel (Invitrogen), transferred to nitrocellulose membrane, and
hybridized with
32P-end-labeled probes specific for miR-22 at
42uC for 16 hours. The miR-22 probe, 59-TAAAGCTTGC-
CACTGAAGAACT-39 was synthesized by Integrated DNA
Technologies; all other reagents were purchased from Applied
Biosystems.
Quantitative Real-Time PCR (qRT-PCR)
To analyze miRNA expression, TaqMan MicroRNA assays
were used to quantify levels of mature miRNAs following the
manufacturer’s instructions. Briefly cDNA was synthesized from
purified small RNA (10 ng) and performed Real-Time PCR by
using iCycler iQ (BioRad). Expression levels were normalized to
U6. The primers for miRNA RT-PCR and the PCR mix were
purchased from Applied Biosystems. To detect mRNA expression,
cDNA synthesis was performed using High Capacity cDNA
synthesis kit (Applied Biosystems). The primers for human VEGF
and ß-actin were purchased from Applied Biosystems.
Luciferase Assays
A fragment of the 39 UTR of HIF-1a (starting after the TGA
stop codon and extending for 401 bp) containing the miR-22
response element was cloned into pMIR-REPORT luciferase
vector (Applied Biosystems). Mutation of the miR-22 response
element (59-GTTGACGG-39 R 59-GATCAGGG -39) was made
by QuikChange Site-Directed Mutagenesis kit (Stratagene).
HCT116 cells were plated at 5610
4 cells per well in 24 well
plates. Next day, pMIR-REPORT Luciferase vectors including 39
UTR of HIF-1a and precursor miR-22 or scrambled oligonucle-
otides were transfected into cells using Lipofectamine 2000
Figure 5. MiR-22 inhibits HCT116 production of VEGF and stimulation of endothelial cells. HCT116 cells were transfected with pre-miR-22
or control, and the media were collected. (A) HUVEC cells were grown in 12 well plates, the conditioned media were added, and the HUVEC were
incubated for 3 days. Proliferation was monitored by BrdU incorporation assay (n=56 S.D. *P,0.05). Pre-miR-22 decreases the ability of hypoxic
treated cells to produce factors that stimulate endothelial proliferation. (B) HUVEC cells were scratched, the conditioned media were added, and
photographed at 16 h. (C) Measurement of the distance covered by each wound relative to the control exposed with normoxia. (*P,0.05)
doi:10.1371/journal.pone.0020291.g005
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were performed using the dual luciferase reporter assay system
(Promega).
Western blotting
Cells were lysed in 0.4 ml of lysis buffer (50 mM Tris pH 8.0,
150 mM NaCl, 10 mM EDTA, 1% NP40, 20 mM NaF, 1 mM
orthovanadate and protease inhibitor cocktail). Lysates were
separated by electrophoresis, blotted to membrane and reacted
with specific antibodies. Antibody to mouse HIF-1a was from Cell
Signaling Technology (Danvers, MA). All other primary antibod-
ies and appropriate secondary antibodies were from Santa Cruz.
VEGF Concentrations
An ELISA was used to quantitate VEGF secreted from
HCT116 cells into the media. HCT116 cells were incubated in
1 ml of media with 1% FBS in the absence (controls) or presence
of DFX or under normoxia or hypoxia for 24 h at 37uC. The
supernatants were assayed for VEGF production using the Human
VEGF ELISA kit according to the manufacturer’s protocol (R&D
Systems).
BrdU incorporation assay
HCT116 or HeLa cells were transfected with Pre-miR-22 or
Pre-miR-control and cultured for 72 hours. BrdU was added to
each wells and incubated for 4 hours. After fixing cells, the cells
were incubated with anti-BrdU antibody for 1 hour, then with
Peroxidase Conjugated Goat anti-Mouse IgG for 30 min. TMB
Peroxidase Substrate was added to each wells. Read the plate
using a spectrophotometer microplate reader set at a wavelength
of 450 nm.
Wound healing assay
HUVECs were seeded on 12 well plates and grown to
confluent. A scratch was performed using a 1000 ml pipette tip
and media change to condition media from HCT116 transfected
with Pre-miR-control or Pre-miR-22. Images were captured at
16 h and the distances between the cells were measured.
Statistical analysis
Data were expressed as the mean 6 SD. Statistical comparisons
were made between two groups with the t test and between
multiple groups by ANOVA. A value of P,0.05 was considered
significant.
Supporting Information
Figure S1 HIF-1b is not a target of miR-22. Description:
HCT116 cells were transfected with pre-miR-22 or pre-miR-
control, and exposed to normoxia or hypoxia for 16 h. Cell lysates
were immunoblotted for HIF-1a and HIF-1b. Over-expression of
miR-22 inhibits HIF-1a expression, but not HIF-1b.
(TIF)
Figure S2 MiR-22 regulates the expressions of angio-
genic factors. Description: HCT116 cells were transfected with
pre-miR-22 or control, and then exposed to normoxia or hypoxia
for 8 h. RNAs from cell lysates were analyzed for angiopoietin 2
(ANGPT-2), stem cell factor (SCF), and COX-2 mRNAs by qPCR
(n=36 S.D. *P,0.05) Over-expression of miR-22 decreased the
expressions of angiogenic factors.
(TIF)
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